N Alpha Methyl Histamine Versus Propranolol in Migraine Prophylaxis

To compare the efficacy and tolerability of the subcutaneous administration of N alpha methyl histamine versus oral propranolol in the treatment of migraine prophylaxis. N alpha methyl histamine has a selective affinity for H3 receptors and could constitute a new therapeutic drug in migraine prophyl...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of neurological sciences 2014-03, Vol.41 (2), p.233-238
Main Authors: Millán-Guerrero, R.O., Isais-Millán, R., Guzmán-Chávez, B., Castillo-Varela, G.
Format: Article
Language:English
Subjects:
Administration, Oral
Adrenergic beta-Antagonists - therapeutic use
Adult
Double-Blind Method
Female
Histamine Agonists - therapeutic use
Humans
Injections, Subcutaneous
Male
Methylhistamines - therapeutic use
Middle Aged
Migraine Disorders - prevention & control
Original Article
Propranolol - therapeutic use
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To compare the efficacy and tolerability of the subcutaneous administration of N alpha methyl histamine versus oral propranolol in the treatment of migraine prophylaxis. N alpha methyl histamine has a selective affinity for H3 receptors and could constitute a new therapeutic drug in migraine prophylaxis. Sixty patients with migraine were selected and enrolled in a 12-week double-blind controlled clinical trial to evaluate the efficacy of subcutaneous administration of N-alpha methyl histamine (1 to 3 ug twice a week ) n=30, compared to administration of 120 mg/day of oral propranolol n=30. the variables were: headache intensity, frequency of attacks, duration of migraine attacks and analgesic intake. fifty five patients completed the study. the data collected during the 4th week of treatment revealed that N alpha methyl histamine and propranolol caused a significantly (p
ISSN:0317-1671
2057-0155
DOI:10.1017/S0317167100016632